| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | CD274, B7H1, B7-H1, PDram Death Ligand-L1, Prog |
| Conjugate | |
| Formulation | |
| Host | |
| Product Type | |
| Shipping | |
| Storage |
Scientific Background
CD274 (B7-H1, PD-L1, Programmed Death Ligand) is a member of the B7 family and is expressed on a variety of tissues including lymphoid cells. It plays an important role in regulation of T cell activation, and is involved in progression of cancer, arthritis and HIV infection (3). CD274 binding to its receptor CD279 (PD-1) on activated T cells can decrease proliferation. Conversely, ligation of CD279 on primed T cells can stimulate IL-10 production. High levels of CD274 present in Renal cell carcinoma are associated with poor prognosis (1). Tumor expressed CD274 can increase apoptosis of tumor specific T cells resulting in better tumor cell survival (2). Gamma Interferon and PHA can up regulate CD274 expression on T cells.
Product Description
CHO CellsRecombinant hCD274 (B7-H1)-muIg is a recombinant human fusion protein produced in CHO Cells cells. Molecular Structure: A soluble fusion protein consisting of the murine CD8 alpha leader sequence, the mature extracellular (224aa) domain of human CD274 fused to murine IgG2a Fc + hinge (233aa).
Alternative names: CD274, B7H1, B7-H1, PDram Death Ligand-L1, Prog
Protein Specifications
| Fusion Format | Murine IgG Fc Fusion (muIg) |
|---|---|
| Expression System | CHO Cells |
| Molecular Weight | 54.4 kDa |
| Formulation | 50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl, 0.5% Gentamicin sulfate |
| Storage | Store at 2 - 5°C. Freeze/Thawing is not recommended. |
| Species Reactivity | Human |
| Validated Applications | ELISA |
| Available Conjugates | Biotin, Unconjugated |
✔ Research Use Only (RUO)
Safety & Handling
Research Use Only. Not intended for diagnostic, therapeutic, or clinical use. Handle according to good laboratory practice (GLP). Consult the Safety Data Sheet (SDS) prior to use.
Related Products
Browse our full collection of recombinant proteins and antibodies for immunology and immune checkpoint research.
This protein was expressed in CHO Cells cells. Mammalian expression is critical for this Fc fusion protein because it ensures proper glycosylation and tertiary folding of the extracellular immunoglobulin-like domains, preserving native receptor-binding activity.
Recombinant hCD274 (B7-H1)-muIg has been validated for: ELISA. It is produced as a Murine IgG Fc Fusion (muIg), making it suitable as a blocking reagent, binding standard, or functional stimulant/inhibitor in immunology assays.
Recommended storage: Store at 2 - 5°C. Freeze/Thawing is not recommended.. Formulation: 50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl, 0.5% Gentamicin sulfate. Avoid repeated freeze-thaw cycles. If long-term storage is needed, aliquot upon first use.
Species reactivity includes: human. Cross-reactivity was confirmed by functional binding assays (e.g., ELISA and/or FACS) against cells or recombinant proteins from the indicated species.
Available formats include: Biotin, Unconjugated. Conjugated forms are ready-to-use without secondary detection reagents for flow cytometry. Unconjugated (purified) forms can be used with anti-Fc secondary antibodies in ELISA.
Can't Find What You're Looking For? We can help you source the best match or customize a recombinant protein solution for your study. Options may include species (human/mouse/rat), protein region/domain (full-length vs fragment), tag or label (His/GST/FLAG/biotin/fluorescent), expression system (E. coli/HEK293/insect), purity grade, formulation (buffer, carrier-free, glycerol-free), activity/functional validation (binding or enzymatic assays), endotoxin level (low-endotoxin for cell-based work), mutants/variants (point mutations, isoforms), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
- Cancer Research (April 2006) 66:3381.
- J Molecular Medicine (Feb 2004) 81(5):281.
- Int J Hematol (Nov 2003) 78(4):321.
